Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Adverum Biotechnologies (NASDAQ:ADVM) announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Laurent Fischer, MD, President and CEO, along with Szilárd Kiss, MD, Distinguished Professor of Ophthalmology and Board Member, will engage in a fireside chat on August 13, 2025, at 9:00 AM EDT.
The presentation will be accessible via live webcast through Adverum's website investor section, with a replay available for at least 30 days after the event.
Adverum Biotechnologies (NASDAQ:ADVM) ha annunciato la sua partecipazione al prossimo H.C. Wainwright 5° Congresso Annuale Virtuale di Oftalmologia. Laurent Fischer, MD, Presidente e CEO, insieme a Szilárd Kiss, MD, Professore Distinto di Oftalmologia e Membro del Consiglio di Amministrazione, parteciperanno a una conversazione informale il 13 agosto 2025 alle 9:00 AM EDT.
La presentazione sarà fruibile in diretta streaming tramite la sezione investitori del sito web di Adverum, con la possibilità di rivederla per almeno 30 giorni dopo l’evento.
Adverum Biotechnologies (NASDAQ:ADVM) anunció su participación en la próxima 5ª Conferencia Anual Virtual de Oftalmología de H.C. Wainwright. Laurent Fischer, MD, Presidente y CEO, junto con Szilárd Kiss, MD, Profesor Distinguido de Oftalmología y Miembro del Consejo, participarán en una charla informal el 13 de agosto de 2025 a las 9:00 AM EDT.
La presentación estará disponible en transmisión en vivo a través de la sección de inversores del sitio web de Adverum, con una repetición accesible por al menos 30 días después del evento.
Adverum Biotechnologies (NASDAQ:ADVM)가 다가오는 H.C. Wainwright 제5회 연례 안과 가상 컨퍼런스에 참여한다고 발표했습니다. Laurent Fischer, MD 대표이사 겸 CEO와 Szilárd Kiss, MD 안과 명예 교수이자 이사회 멤버가 2025년 8월 13일 오전 9시 EDT에 화기애애한 대화를 진행할 예정입니다.
발표는 Adverum 웹사이트 투자자 섹션을 통해 실시간 웹캐스트로 시청 가능하며, 행사 후 최소 30일간 다시보기 서비스를 제공합니다.
Adverum Biotechnologies (NASDAQ:ADVM) a annoncé sa participation à la 5e Conférence Annuelle Virtuelle d’Ophtalmologie organisée par H.C. Wainwright. Laurent Fischer, MD, Président et CEO, ainsi que Szilárd Kiss, MD, Professeur Distingué en Ophtalmologie et membre du conseil d’administration, participeront à une discussion informelle le 13 août 2025 à 9h00 EDT.
La présentation sera accessible en direct via un webcast sur la section investisseurs du site web d’Adverum, avec une rediffusion disponible pendant au moins 30 jours après l’événement.
Adverum Biotechnologies (NASDAQ:ADVM) gab seine Teilnahme an der bevorstehenden 5. jährlichen virtuellen Ophthalmologie-Konferenz von H.C. Wainwright bekannt. Laurent Fischer, MD, Präsident und CEO, sowie Szilárd Kiss, MD, angesehener Professor für Ophthalmologie und Vorstandsmitglied, werden am 13. August 2025 um 9:00 Uhr EDT an einem informellen Gespräch teilnehmen.
Die Präsentation ist als Live-Webcast über den Investor-Bereich der Adverum-Website zugänglich, mit einer Wiederholung, die mindestens 30 Tage nach der Veranstaltung verfügbar sein wird.
- None.
- None.
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025 at 9:00am EDT.
A live webcast of the fireside chat can be accessed in the Investors section of Adverum’s website at www.adverum.com. An archived replay of the webcast will be available for at least 30 days following the presentation.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases with the aspirations of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Corporate and Investor Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
Media:
Jason Awe, Ph.D.
Executive Director, Corporate Communications
Email: jawe@adverum.com
FAQ
When is Adverum Biotechnologies (ADVM) presenting at the H.C. Wainwright Ophthalmology Conference?
Who will represent Adverum Biotechnologies at the H.C. Wainwright Conference?
How can investors access Adverum's presentation at the H.C. Wainwright Conference?
How long will the replay of Adverum's H.C. Wainwright Conference presentation be available?
